Infantile Hemangioma
Conditions
Interventions
experiment group:Local application of Dex-Pro SRF
Control group:Intratumoral injection of triamcinolone acetonide
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age from birth to 1 year old (Infant hemangioma of the eye occurs at most within 3 months after birth, and then grows faster in the next 3 months. After 1 year old, the lesion tends to be stationary, and some have spontaneous tendency to regress); 2. Gender: male or female; 3. Course of disease less than 1 year; 4. Indications: Patients diagnosed with infantile hemangioma (IH); (1) Surface IH involving the dermis of the skin (eyelids and face or body); (2) Hybrid IH that simultaneously invades the skin and subcutaneous tissue or deep eyelids; 5. Meet any of the following clinical manifestations: (1) Rapid tumor growth; (2) Significant deformities of eyelids or orbits caused by the location of tumors affect the appearance; (3) The tumor blocks the eye and has the risk of forming amblyopia; (4) Tumor compression eyeball displacement and protrusion; 6. The subject's guardian has a strong need for treatment, fully understands the condition, and signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Hemangioma of large area, covering special parts of the body or skin, should be given special care, under the strict surveillance of pediatricians, medication treatment; 2. During the period of acute upper respiratory tract infection, acute bronchitis, bronchiolitis and bronchopneumonia; 3. Infants with congenital maldevelopment of other organs; 4. abnormal heart, liver and kidney functions; 5. those who have allergic history to many drugs; 6. Any medical history, according to the investigator's judgment, may interfere with the test results or increase the risk of patients; 7. Those who have been treated with glucocorticoid in half a year; 8. Those who had been treated with beta blockers within half a year; 9. Participants in other drug clinical trials in the last three months; 10. Those who cannot follow up on schedule or cooperate with researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor size; | — |
Countries
China
Contacts
Public ContactLin Tingting
Tianjin Medical University Eye Hospital
Outcome results
None listed